Donate
T1International Statement on ADA Insulin Price Petition

T1International Statement on ADA Insulin Price Petition

Facebook Google LinkedIn Twitter

Recently, the American Diabetes Association issued a resolution and launched a  petition calling for more access to affordable insulin. 

It is fantastic to see a large diabetes organization speaking out in this way. However, we feel that the ADA’s language around the call for price transparency does not go far enough. With insulin costs forcing people to choose between paying rent and buying their medicine, patients deserve to know exactly where their money is going. Only when there is complete transparency from all players will we have a full understanding of the high costs of insulin.

T1International is also disappointed to see that the ADA has not reached out to those of us in the diabetes space who are already working on this issue and have been carrying out similar initiatives for some time. We hope to see more collaboration from patient organisations so that no one is duplicating efforts and everyone who wants to take action can do so with one powerful, united voice.

We look forward to the opportunity to work with the ADA and other organisations to push for #insulin4all, and hope to add an additional global perspective on both availability and affordability of insulin and diabetes supplies.


For further information please contact:

Elizabeth Rowley, Director, T1International, elizabeth@t1international.com

T1International is a registered Charity in the UK that works towards adequate access to insulin, diabetes supplies, medical care and education for all people living with type 1 diabetes. They do this by raising awareness, campaigning and collaborating with existing initiatives, and supporting individuals and organisations on the ground that are working to make life better for people with type 1 diabetes.

Related posts:

T1International Statement on Scientific Independence and the Freedom to Speak Without Fear

T1International Statement on Scientific Independence and the Freedom to Speak Without Fear


T1International's Federal Working Group issued this statement in response to clinicians being removed from the ADA's 85th Scientific Sessions after sharing a published editorial on science and public policy — an event that raised serious concerns about academic freedom and the ability of researchers to speak without fear of retaliation. As a pharma-free, patient-led organization, T1International holds that scientific independence is not abstract: when researchers self-censor or institutions suppress open dialogue, people with diabetes bear the consequences through delayed progress and reduced transparency. T1International stands with researchers and clinicians who defend scientific integrity, and commits to continuing its history of speaking truth to power on behalf of the diabetes community. Read more

T1International Statement on Insulin Manufacturer's Responses to COVID-19

T1International Statement on Insulin Manufacturer's Responses to COVID-19

The best way for insulin manufacturers to demonstrate their commitment to patient health would be for them to permanently lower their list price, which would make low-cost insulin easier to acquire and apply to every patient who needs it. Read more

T1International Statement on COVID-19

T1International Statement on COVID-19

As the world grapples with the effects of a global pandemic, the situation is evolving quickly and the short and long-term impacts are still unclear. What is clear is that the COVID-19 crisis stresses the need to approach healthcare as a human right. The crisis also emphasizes the need for international cooperation to fix global health problems. There must be global solidarity in the fight for #insulin4all and universal access to healthcare. Read more

T1International Statement on Walmart Insulin

T1International Statement on Walmart Insulin

Recently, the American Diabetes Association issued a white paper on Insulin Access and Affordability by their Working Group. While we continue to applaud the American Diabetes Association for speaking out about the high cost of insulin, we remain concerned with their approach and some of the recommendations in their paper.
Read more

T1International Testimony for Insulin Access & Affordability: The Rising Cost of Treatment

T1International Testimony for Insulin Access & Affordability: The Rising Cost of Treatment

T1International’s 2018 global survey explored out-of-pocket costs for people with type 1 diabetes. More than 25% of American respondents said that they have had to ration insulin at least once per year due to cost. Fourteen percent of those respondents have had to ration their insulin monthly, weekly, or daily due to insulin cost. Read more